Additionally, advanced salvage options—such as repeat SRS and systemic therapies effective for intracranial and extracranial disease (e.g., melanoma and NSCLC with EGFR mutations or ALK translocations)—challenge the routine use of WBRT. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.